申请人:ChemoCentryx, Inc.
公开号:US09169248B2
公开(公告)日:2015-10-27
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
提供了一系列作为CCR1受体的有效拮抗剂的化合物,并具有体内抗炎活性。这些化合物是咪唑环内酰胺衍生物,可用于制备药物组合物,治疗CCR1介导的疾病的方法,以及作为竞争性CCR1拮抗剂鉴定的控制物。